- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
- Details
- Francesco Soria discusses a study validating the IBCG scoring system for intermediate-risk bladder cancer. He explains the heterogeneity of this risk group and the need for better stratification. Soria describes the IBCG model, which uses five risk factors to divide patients into three subgroups. The study validates this model using a large European cohort, showing significant differences in recur...
|
- Details
- Ashish Kamat interviews Felix Guerrero-Ramos about a European Urology Oncology review on novel treatments for non-muscle-invasive bladder cancer (NMIBC). Dr. Guerrero-Ramos presents an overview of emerging therapies across different risk categories of NMIBC, focusing on intravesical and systemic approaches. He highlights FDA-approved treatments for BCG-unresponsive disease and ongoing trials for B...
|
- Details
- In this discussion, Sam Chang interviews Saum Ghodoussipour about the role of circulating tumor DNA (ctDNA) as a biomarker in urothelial carcinoma. Dr. Ghodoussipour presents an overview of ctDNA's potential applications in various stages of bladder cancer, from non-muscle invasive to advanced disease. He highlights its utility in early detection, risk stratification, and monitoring treatment resp...
|
- Details
- Sam Chang host Paul Crispen to discuss his study on BCG efficacy in patients with upper tract urothelial carcinoma following nephroureterectomy. Dr. Crispen discusses the findings, which show that patients with a history of upper tract disease experience bladder tumor recurrences sooner than those with primary bladder tumors, despite similar overall recurrence rates. The study reveals a higher ris...
|
- Details
- Therapeutic options for patients with non-muscle-invasive bladder cancer (NMIBC) have traditionally been limited to intravesical immunotherapy or chemotherapy. A considerable number of new options have been investigated in recent years. Our aim was to review the efficacy and toxicity of novel therapeutic options (results already reported or currently under investigation) for patients with NMIBC. B...
|
- Details
- Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase one study showing promising results with minimal toxicity. The treatment activates dendritic cells, leading to CD8+ T cell recruitment and tumor elimination. Preliminary data indicates a 50% complete...
|
- Details
- Sam Chang interviews Sunil Patel about the Orion Bladder Cancer Study. The phase 3 single-arm study evaluates the efficacy and safety of a paclitaxel-hyaluronic acid conjugate, ONCOFID-P-B, administered intravesically for patients with BCG-unresponsive CIS of the bladder. This novel agent targets CD44, overexpressed in bladder cancer cells, and has shown promising results with a high complete resp...
|
- Details
- Sam Chang interviews Roger Li about the MoonRISe-1 trial. This phase 3 study explores the use of TAR-210, an innovative intravesical delivery system for the tyrosine kinase inhibitor erdafitinib, targeting patients with intermediate-risk non-muscle-invasive bladder cancer harboring FGFR alterations. Dr. Li explains that TAR-210, administered via a quick in-office procedure, continuously releases e...
|
- Details
- Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment. Speaking with Dr. Sam Chang of Vanderbilt, Dr. Porten explains that TAR-200 releases gemcitabine directly into the bladder over a sustained period, offeri...
|